1
|
Gao F, Sihver W, Bergmann R, Walther M, Stephan H, Belter B, Neuber C, Haase-Kohn C, Bolzati C, Pietzsch J, Pietzsch HJ. Radiochemical and radiopharmacological characterization of a 64 Cu-labeled α-MSH analog conjugated with different chelators. J Labelled Comp Radiopharm 2019; 62:495-509. [PMID: 30912594 DOI: 10.1002/jlcr.3728] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 03/01/2019] [Accepted: 03/08/2019] [Indexed: 02/06/2023]
Abstract
Radiolabeled α-melanocyte-stimulating hormone (α-MSH) derivatives have a high potential for diagnosis and treatment of melanoma, because of high specificity and binding affinity to the melanocortin-1 receptor (MC1R). Hence, the α-MSH-derived peptide NAP-NS1 with a β-Ala linker (ε-Ahx-β-Ala-Nle-Asp-His-D-Phe-Arg-Trp-Gly-NH2 ) was conjugated to different chelators: either to NOTA (p-SCN-Bn-1,4,7-triazacyclononane-1,4,7-triacetic acid), to a hexadentate bispidine carbonate derivative (dimethyl-9-(((4-nitrophenoxy)carbonyl)oxy)-2,4-di(pyridin-2-yl)-3,7-bis(pyridin-2-ylmethyl)-3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylate), or to DMPTACN (p-SCN-Ph-bis(2-pyridyl-methyl)-1,4,7-triaza-cyclononane), labeled with 64 Cu, and investigated in terms of radiochemical and radiopharmacological properties. For the three 64 Cu-labeled conjugates negligible transchelation, suitable buffer and serum stability, as well as appropriate water solubility, was determined. The three conjugates exhibited high binding affinity (low nanomolar range) in murine B16F10, human MeWo, and human TXM13 cells. The Bmax values of [64 Cu]Cu-bispidine-NAP-NS1 ([64 Cu]Cu-2) and [64 Cu]Cu-DMPTACN-NAP-NS1 ([64 Cu]Cu-3) were higher than those of [64 Cu]Cu-NOTA-NAP-NS1 ([64 Cu]Cu-1), implying that different charged chelate units might have an impact on binding capacity. Preliminary in vivo biodistribution studies suggested the main excretion pathway of [64 Cu]Cu-1 and [64 Cu]Cu-3 to be renal, while that of [64 Cu]Cu-2 seemed to be both renal and hepatobiliary. An initial moderate uptake in the kidney decreased clearly after 60 minutes. All three 64 Cu-labeled conjugates should be considered for further in vivo investigations using a suitable xenograft mouse model.
Collapse
Affiliation(s)
- Feng Gao
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.,School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany
| | - Wiebke Sihver
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Ralf Bergmann
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Martin Walther
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Holger Stephan
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Birgit Belter
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Christin Neuber
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Cathleen Haase-Kohn
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Cristina Bolzati
- Italian National Research Council - CNR, Institute of Condensed Matter Chemistry and Energy Technologies ICMATE-CNR, Padova, Italy
| | - Jens Pietzsch
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.,School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany
| | - Hans-Jürgen Pietzsch
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.,School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany
| |
Collapse
|
2
|
Sudareva N, Suvorova O, Saprykina N, Smirnova N, Bel'tyukov P, Petunov S, Radilov A, Vilesov A. Two-level delivery systems based on CaCO3 cores for oral administration of therapeutic peptides. J Microencapsul 2019; 35:619-634. [DOI: 10.1080/02652048.2018.1559247] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Natalia Sudareva
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Saint Petersburg, Russian Federation
| | - Olga Suvorova
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Saint Petersburg, Russian Federation
| | - Natalia Saprykina
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Saint Petersburg, Russian Federation
| | - Natalia Smirnova
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Saint Petersburg, Russian Federation
| | - Petr Bel'tyukov
- Occupational Pathology and Human Ecology, Research Institute of Hygiene, Kuzmolovsky, Russian Federation
| | - Sergey Petunov
- Occupational Pathology and Human Ecology, Research Institute of Hygiene, Kuzmolovsky, Russian Federation
| | - Andrey Radilov
- Occupational Pathology and Human Ecology, Research Institute of Hygiene, Kuzmolovsky, Russian Federation
| | - Alexander Vilesov
- Institute of Macromolecular Compounds, Russian Academy of Sciences, Saint Petersburg, Russian Federation
- I.P.Pavlov St. Petersburg Medical University, Saint Petersburg, Russian Federation
| |
Collapse
|
3
|
Sudareva N, Suvorova O, Saprykina N, Vilesov A, Bel'tiukov P, Petunov S, Radilov A. Two-level delivery systems for oral administration of peptides and proteins based on spore capsules of Lycopodium clavatum. J Mater Chem B 2017; 5:7711-7720. [DOI: 10.1039/c7tb01681f] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Two-level delivery systems for oral administration of therapeutic proteins and peptides were developed.
Collapse
Affiliation(s)
- Natalia Sudareva
- Institute of Macromolecular Compounds of the Russian Academy of Science
- St. Petersburg
- Russian Federation
| | - Olga Suvorova
- Institute of Macromolecular Compounds of the Russian Academy of Science
- St. Petersburg
- Russian Federation
| | - Natalia Saprykina
- Institute of Macromolecular Compounds of the Russian Academy of Science
- St. Petersburg
- Russian Federation
| | - Alexander Vilesov
- Institute of Macromolecular Compounds of the Russian Academy of Science
- St. Petersburg
- Russian Federation
- I.P. Pavlov St. Petersburg Medical University
- St. Petersburg
| | - Petr Bel'tiukov
- Research Institute of Hygiene
- Occupational Pathology and Human Ecology
- Leningrad Region
- Russian Federation
| | - Sergey Petunov
- Research Institute of Hygiene
- Occupational Pathology and Human Ecology
- Leningrad Region
- Russian Federation
| | - Andrey Radilov
- Research Institute of Hygiene
- Occupational Pathology and Human Ecology
- Leningrad Region
- Russian Federation
| |
Collapse
|
4
|
Savos AV, Gee JM, Zierath D, Becker KJ. α-MSH: a potential neuroprotective and immunomodulatory agent for the treatment of stroke. J Cereb Blood Flow Metab 2011; 31:606-13. [PMID: 20700130 PMCID: PMC3049515 DOI: 10.1038/jcbfm.2010.130] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Alpha-melanocyte-stimulating hormone (MSH) is a neuropeptide with profound immunomodulatory properties; we evaluated the effects of α-MSH on stroke outcome and its ability to modulate the postischemic immune response. In Lewis rats subjected to 3 hours of middle cerebral artery occlusion (MCAO), plasma concentrations of α-MSH rapidly decreased and returned to baseline over the course of days. Exogenous administration of α-MSH (100 or 500 μg/kg) improved 24 hour outcome in animals subjected to 2 hours MCAO; α-MSH 500 μg/kg also decreased infarct volume at this time point. Both doses of α-MSH were ineffective in improving outcome or decreasing infarct volume in animals subjected to 3 hours MCAO. The splenocyte response to phytohemagglutin in animals treated with α-MSH was attenuated at 24 hours after MCAO. At 1 month after MCAO, treatment with α-MSH 500 μg/kg at the time of stoke was associated with a decrease in TH1 response to myelin basic protein (MBP) in animals subjected to 2 hours MCAO, although treatment was not associated with improved outcome at this time point. Given the early benefits of α-MSH treatment and its effect on immunologic outcome, further studies to evaluate the utility of α-MSH for the treatment of cerebral ischemia are warranted.
Collapse
Affiliation(s)
- Anna V Savos
- Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
| | | | | | | |
Collapse
|
5
|
Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997; 99:1165-72. [PMID: 9077523 PMCID: PMC507929 DOI: 10.1172/jci119272] [Citation(s) in RCA: 232] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Reperfusion after ischemia induces cytokines, chemoattractant chemokines, adhesion molecules, and nitric oxide (NO). The resultant neutrophil adherence and NO potentiates renal injury. alpha-Melanocyte-stimulating hormone (alpha-MSH) is a potent anti-inflammatory agent that inhibits neutrophil migration and production of neutrophil chemokines and NO. Since neutrophils and NO promote renal ischemic injury, we sought to determine if alpha-MSH inhibits renal injury in a model of bilateral renal ischemia. alpha-MSH significantly reduced ischemia-induced renal damage, measured by changes in renal histology and plasma blood urea nitrogen and creatinine in mice. alpha-MSH significantly decreased tubule necrosis, neutrophil plugging, and capillary congestion. Delay of alpha-MSH treatment for 6 h after ischemia also significantly inhibited renal damage. alpha-MSH also significantly inhibited ischemic damage in rats. To begin to determine the mechanism of action of alpha-MSH, we measured its effects on mediators of neutrophil trafficking and induction of the inducible isoform of NO synthase-II. alpha-MSH inhibited ischemia-induced increases in mRNA for the murine neutrophil chemokine KC/IL-8. alpha-MSH also inhibited induction of mRNA for the adhesion molecule ICAM-1, which is known to be critical in renal ischemic injury. alpha-MSH inhibited nitration of kidney proteins and induction of NO synthase-II. We conclude: (a) alpha-MSH protects against renal ischemia/reperfusion injury; and (b) it may act, in part, by inhibiting the maladaptive activation of genes that cause neutrophil activation and adhesion, and induction of NO synthase.
Collapse
Affiliation(s)
- H Chiao
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-8856, USA
| | | | | | | | | | | |
Collapse
|
6
|
Affiliation(s)
- A J Kastin
- Veterans Affairs Medical Center, University of New Orleans, Tulane University School of Medicine, New Orleans, Louisiana 70146, USA
| | | | | | | |
Collapse
|
7
|
Abstract
Though birds lack the pars intermedia of the hypophysis, their pituitary glands do secrete MSH. This hormone and ACTH are elaborated in special cells of the pars distalis called corticomelanotrops. The present study was designed to ascertain whether the release of MSH in aves is under either stimulatory or inhibitory hypothalamic control. Extracts of median eminence were injected in ducks and plasma MSH was observed to rise after the injections: on the other hand, when pituitaries were ectopically grafted, significant changes in the levels of circulating MSH were not detected. Twenty days after grafting, the transplants were extirpated and incubated in media containing median eminence extracts. The extracts stimulated the release of MSH not only from grafts but also from pieces of normotopic glands. The grafts showed cells which contained ACTH but not MSH; however, they contained small amounts of MSH, detectable by RIA. The administration of ergocryptine brought about the inhibition of MSH secretion in vivo, and it is suggested that this drug acted on hypothalamic structures rather than directly on the corticomelanotrops. On the basis of the preceding results, it is concluded for the first time that in ducks the release of MSH has stimulatory control from the hypothalamus, contrarily to that occurring in almost all the animals so far investigated.
Collapse
|
8
|
Wilkes BC, Hruby VJ, Yamamura HI, Akiyama K, Castrucci AM, Hadley ME, Andrews JR, Wan YP. Synthesis of tritium labeled Ac-[Nle4, D-Phe7]-alpha-MSH4-11-NH2: a superpotent melanotropin with prolonged biological activity. Life Sci 1984; 34:977-84. [PMID: 6608041 DOI: 10.1016/0024-3205(84)90302-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Ac-[Nle4, D-Phe7]-alpha-MSH4-11-NH2 an octapeptide, is a melanotropin analogue (Ac-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-NH2), which is a superpotent agonist of frog and lizard skin melanocytes and mouse S 91 (Cloudman) melanoma cells. This melanotropin possesses ultraprolonged activity on melanocytes, both in vitro and in vivo, and the peptide is resistant to inactivation by serum enzymes. The tritium-labeled congener was prepared by direct incorporation of [3H]-labeled norleucine into the peptide. The melanotropic activity of the labeled peptide is identical to the unlabeled analogue. This labeled peptide should be useful for studies on the localization and characterization of melanotropin receptors.
Collapse
|
9
|
Abstract
Peptide research, like all of science, requires a careful balance between building upon previously accumulated knowledge and exploring perspectives that are in conflict with prevailing views. Many of the concepts discussed here originally stimulated certain lines of research. The downfall of most of these concepts, and thus their misleading nature, lies in the limitation of possible modes by which peptides are perceived to affect the functioning of the central nervous system (CNS).
Collapse
|
10
|
Abstract
Pentobarbitone anesthetized rats were injected with 30 nmol (50 micrograms) alpha-MSH administered intraperitoneally (IP) and subcutaneously (SC) in an acid-saline vehicle, or SC in a zinc phosphate vehicle. Concentrations of alpha-MSH in plasma were measured by radioimmunoassay. The pharmacokinetic parameters for the three modes of administration were determined by fitting a one-compartment open model to the plasma level data. The t1/2 for absorption using the saline vehicle was 7.3 and 5.6 min from the IP and SC sites, respectively. The t1/2 for absorption from the zinc phosphate complex of 17.7 min was significantly longer. Five percent of the IP dose was absorbed into the systemic circulation giving a peak plasma level of 14.1 nmol/l. The absorption of 2-3 percent was significantly lower following SC administration; peak plasma levels were 8.3 and 4.8 nmol/l for the saline and zinc phosphate vehicles, respectively. The low percentage absorption values indicated a high degree of metabolism of the peptide by peripheral tissues on its passage from the injection sites into the circulation.
Collapse
|
11
|
Kastin AJ, Fabre LA. Limitations to effect of alpha-MSH on permeability of blood-brain barrier to IV 99mTc-pertechnetate. Pharmacol Biochem Behav 1982; 17:1199-201. [PMID: 6298832 DOI: 10.1016/0091-3057(82)90120-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The effects of several variables on the permeability of the blood-brain barrier (BBB) to 99mTc-labeled sodium pertechnetate after IV administration of alpha-MSH were investigated. Doses of alpha-MSH of about 200 micrograms/kg were generally more effective in increasing the brain:blood ratio of radioactivity than the smaller doses that had previously been shown to affect behavior and the EEG. Pulsatile administration of a total of 200 micrograms/kg alpha-MSH over 90 min did not change the permeability of the BBB to the pertechnetate anion. Infusion of the same dose over 90 min significantly increased the brain:blood ratio of radioactivity in one of two experiments: no significant effects were seen with infusion for shorter times, lower concentrations, or with a 4-9 analog (Org 2766). In another experiment, bolus injection of 200 micrograms/kg alpha-MSH resulted in a significantly increased ratio 90 min later as compared with controls. Although the effects of a peptide on the permeability of the BBB to other compounds remains intriguing, limitations appear to exist in experiments with 99mTc-pertechnetate.
Collapse
|
12
|
Abstract
alpha-Melanocyte-stimulating hormone (alpha-MSH), a modified fragment of adrenocorticotropic hormone, derives from the same biosynthetic route as beta-endorphin and is stored by the same arcuate neurons. Microinjection of alpha-melanocyte-stimulating hormone and several related peptides into the periaqueductal gray matter significantly reduced responsiveness to pain and had a behavioral profile similar to that produced by beta-endorphin.
Collapse
|